Skin Cutaneous Melanoma(Broad, Cancer Discov 2014)

Summary

Skin Cutaneous Melanoma(Broad, Cancer Discov 2014) is a study catalogued by cBioPortal DataHub under the cancer-type code mel. EvidenceHelix groups it with skin and eye studies.

Study description

Exome Sequencing of tumors (with matched normals) from 45 patients with BRAFV600-mutant metastatic melanoma who received vemurafenib or dabrafenib monotherapy.

Text as published in the source's study metadata.

Citation & PubMed

Van Allen et al. Cancer Discov. 2012

Linked PubMed records: PMID 24265153

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

skcm_broad_brafresist_2012

Short name

SKCM (BROAD 2014)

Source cancer-type code

mel

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Van Allen et al. Cancer Discov. 2012

• PubMed record 24265153 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Acral Melanoma (TGEN, Genome Res 2017)

  Whole exome sequencing and transcriptome analysis of 34 Acral Melanoma patients (33 with matched normals).

  Skin and eyeOther published and consortium studiesSource code melPubMed 1

• Metastatic Melanoma (DFCI, Nat Med. 2019) - iAtlas Harmonized

  Whole-exome sequencing and neoantigen landscape analysis of 122 patients with metastatic melanoma treated with anti-PD1 ICB, along with their matched normal samples. The reprocessing of raw sequencing data is coordina…

  Skin and eyeOther published and consortium studiesSource code melPubMed 1

• Metastatic Melanoma (DFCI, Nature Medicine 2019)

  Whole-exome sequencing of 144 pre-treatment samples from 144 patients with metastatic melanoma treated with anti-PD1 ICB. Related Dataset: A harmonized version with extended neoantigen annotations (122 samples) is ava…

  Skin and eyeOther published and consortium studiesSource code melPubMed 1

• Metastatic Melanoma (Immunotherapy Trial, Cancer Cell 2019) - iAtlas Harmonized

  Whole-exome sequencing and neoantigen landscape analysis of 158 metastatic melanomas treated with anti-PD-1 monotherapy or combined anti-PD-1 and anti-CTLA-4 therapy and their matched normals. A subset of these patien…

  Skin and eyeOther published and consortium studiesSource code melPubMed 1

• Metastatic Melanoma (UCLA, Cell 2016)

  Whole-exome sequencing of 38 pretreated (pembrolizumab, nivolumab) melanoma tumor-normal pairs. Related Dataset: A harmonized version with extended neoantigen annotations (27 samples) is available: iAtlas Harmonized V…

  Skin and eyeOther published and consortium studiesSource code melPubMed 1

• Metastatic Melanoma (UCLA, Cell 2016) - iAtlas Harmonized

  Whole-exome sequencing and neoantigen landscape analysis of 27 pretreatment melanoma tumors and their matched normals. The reprocessing of raw sequencing data is coordinated by CRI iAtlas (https://cri-iatlas.org/). Re…

  Skin and eyeOther published and consortium studiesSource code melPubMed 1

• Melanoma (MSK, Cell 2017) - iAtlas Harmonized

  Whole-exome sequencing and neoantigen landscape analysis of tumors from 64 advanced melanoma patients, profiled before and after nivolumab treatment. The reprocessing of raw sequencing data is coordinated by CRI iAtla…

  Skin and eyeMSK studiesSource code melPubMed 1

• Melanoma (MSK, Clin Cancer Res 2021)

  Targeted sequencing (MSK-IMPACT) of 696 melanoma tumor/normal pairs.

  Skin and eyeMSK studiesSource code melPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.